Category: Business

Categories
Business

AM Best comments on Credit Ratings of Accident Fund Insurance Company of America and subsidiaries following announcement of AmeriTrust Group acquisition

OLDWICK, N.J. — (BUSINESS WIRE) — #insurance—AM Best has commented that the Credit Ratings (ratings) of Accident Fund Insurance Company of America (Accident Fund) (Lansing, MI) and its insurance subsidiaries remain unchanged following the announcement that it has agreed to acquire Star Insurance Company (Southfield, MI) and its subsidiaries (collectively referred to as AmeriTrust Group). The transaction is subject to regulatory approvals and is expected to close before the end of 2022.

On April 12, 2022, Accident Fund announced that it has entered into a definitive agreement to acquire AmeriTrust Group from Fosun International Limited. AmeriTrust offers specialty insurance programs and products, including workers’ compensation, commercial package and automotive business coverages, and comprehensive product offerings in various industry segments.

 

AM Best anticipates that Accident Fund will continue to maintain supportive risk-adjusted capitalization and overall balance sheet strength, which is assessed at the very strong level. AM Best does not expect Accident Fund’s strong operating performance, neutral business profile and appropriate enterprise risk management to be impacted by the transaction. Following the close of the transaction, AM Best will continue to discuss the transaction’s progress with Accident Fund management and assess its impact on operations.

 

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments.

 

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

 

Copyright © 2022 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Michael Venezia
Senior Financial Analyst
+1 908 439 2200, ext. 5034
michael.venezia@ambest.com

Robert Raber
Director
+1 908 439 2200, ext. 5696
robert.raber@ambest.com

Christopher Sharkey
Manager, Public Relations
+1 908 439 2200, ext. 5159
christopher.sharkey@ambest.com

Jim Peavy
Director, Communications
+1 908 439 2200, ext. 5644
james.peavy@ambest.com

Categories
Business Technology

Altada partners with leading data management platform, SlyceData

AI Leader Enters Into Strategic Relationship With Data and Research Platform Company, Delivering Enhanced Decision Making Tools to the Financial Services Market

 

CORK, Ireland & NEW YORK — (BUSINESS WIRE) — Altada Technology Solutions, a global provider of artificial intelligence (AI) solutions that supercharge data-driven decision making in the financial services, travel/security and healthcare sectors, today announced a strategic partnership with SlyceData. SlyceData is a leading data management platform for investment researchers that automates the data wrangling process and provides intuitive tools for exploring and extracting financial data.

The partnership, effective today, will enable joint customers to seamlessly combine data from multiple sources, including those generated by Altada’s AI solutions. SlyceData’s best-in-class solution automates the crucial tasks of ingestion and concordance of data sets, complementing Altada’s suite of financial services AI solutions. Altada uses AI to generate structured datasets from previously inaccessible information, dramatically increasing the number of available data sources for financial services teams. Sharing technology capabilities, the Altada-SlyceData partnership will better serve the data analytics market across a variety of use cases.

 

“We’re excited about this strategic partnership with SlyceData because it greatly expands our technology capabilities,” said Allan Beechinor, Altada CEO. “Together, we will deliver a solution designed to empower professionals within financial institutions to make data-driven decisions as quickly as possible, using the best available data sources.”

 

The vast majority of structured datasets remain incompatible with each other. SlyceData automates time-consuming data preparation, drastically increasing the volume of data that can be utilized for decision making and accelerating the discovery of insights using those datasets.

 

The partnership will enable SlyceData to provide greater value to a wider range of financial institutions, and the combined Altada-SlyceData solution will provide clients with access to new data sources. It will also provide customers with the ability to intuitively explore, extract and visualize their various data sources side-by-side. These advanced capabilities will enable financial institutions to optimize their performance by making data-driven decisions quickly and cost effectively.

 

“We’re delighted to be partnering with Altada, who share our vision for a data-driven future for financial services and beyond,” said Chris Harrison, CEO of SlyceData. “SlyceData provides unique expertise around financial data management and a deep familiarity with the investment management space, while Altada brings the best of breed in AI and machine learning to streamline processes and quickly unlock new sources of data. By sharing our capabilities, we’ll accelerate product development to deliver a compelling solution – focused on data usability and accessibility – that will help firms leverage their data to drive business results.”

 

About Altada

Founded in 2017, Altada is a global provider of artificial intelligence (AI) solutions that supercharge data-driven decision making in the financial services, travel/security and healthcare markets. The company’s Data Intelligence Platform integrates the first AI engine that leverages optical character recognition (OCR) and natural language processing (NLP) to analyze large volumes of structured and unstructured data, enabling users to not only make sense of their information but to also gain meaningful market insights that drive competitive advantage. Altada is headquartered in Cork, Ireland, and operates 12 offices across Europe, the US and Asia, including Dublin, Malta, London, Miami, New York, San Francisco and Delhi. Privately-held, Altada is backed by venture investment from Rocktop Partners, Elkstone Partners and Enterprise Ireland. To learn more, please visit https://www.altada.com/.

 

About Slycedata

Headquartered in New Jersey, SlyceData provides data solutions to financial services firms to accelerate their investment research process. Its suite of tools was developed hand-in-hand with industry partners to fit seamlessly into investors’ workflows. Its team has deep expertise in data engineering and the investment management industry. SlyceData helps firms leverage the abundance of available data sources to deliver insights and drive performance.

Contacts

Altada Contact:
Miranda Honnoll

Bospar for Altada
miranda@bospar.com
(408) 887-8486

SlyceData Contact:
Aoife Manley

hello@slycedata.com
(805) 702-3205

Categories
Business Technology

OwnBackup announces the launch of OwnBackup Secure to help companies address SaaS data security gaps

With Secure, OwnBackup addresses the growing demand to include security as part of a comprehensive data protection strategy

 

ENGLEWOOD CLIFFS, N.J. — (BUSINESS WIRE) — OwnBackup, the leading SaaS data protection platform, today announced the launch of a new SaaS Security Posture Management (SSPM) solution, OwnBackup Secure, to help companies identify data vulnerabilities and proactively take action to protect their mission-critical data.

While cyberattacks continue to be a constant threat to all companies that store data in the cloud, it’s just one trend contributing to a larger data confidence crisis, as the volume, velocity, and variety of data inside SaaS applications grows. As SaaS solutions are adopted across more parts of a business, it’s becoming increasingly difficult for organizations to manage, secure and protect their data while simultaneously driving digital transformation projects – primarily because the security controls provided by SaaS providers become more difficult to manage as data and users scale. According to OwnBackup’s research, 88% of sensitive information inside Salesforce remains exposed to hacking and misuse by employees because most users can read or edit high-risk fields.

 

All of this data also poses compliance challenges, as the data varies considerably in sensitivity levels and is subject to industry-specific or government-mandated regulations such as SOX, HIPAA, PCI DSS, and GDPR. Without a proper SSPM solution, it’s nearly impossible for companies to understand what data they hold in their SaaS applications, who has access to it, and how much damage could be done if it was to be compromised.

 

“Protecting and governing the data inside your SaaS applications has become a massive undertaking,” said Sam Gutmann, CEO of OwnBackup. “Until now, there was no single company that could help organizations manage access to sensitive data through the entire data and application development lifecycle – including classification, security posture analysis, remediation, secure development, backup and recovery, and archiving. With OwnBackup Secure, along with our other products, we’re able to deliver all of those capabilities through a single platform.”

 

OwnBackup Secure is available on the Salesforce AppExchange. The product launch is yet another sign of OwnBackup’s rapid growth and furthers their goal to provide comprehensive data protection that goes beyond backup and recovery. Since acquiring RevCult, a SSPM provider, in the second half of 2021, OwnBackup has accelerated its product investments in security to meet increasing market demands and has gained several new customers in just the past few months.

 

“OwnBackup has helped us at Cadence Bank significantly to build a trusted partnership internally with our compliance and security teams, ” said Carl Lange, VP of Application Systems at Cadence Bank. “Having OwnBackup Secure allows our Salesforce team to focus more on what it does best, development in support of the system, while security and compliance teams can focus on risk, collectively benefiting the bank.”

 

Currently, OwnBackup provides its market-leading SaaS data protection solutions for Salesforce, where they are the top-rated solution on the Salesforce AppExchange, as well as Microsoft Dynamics 365, the second-largest CRM platform globally. Between both ecosystems, OwnBackup now protects over 4,500 customers worldwide. As part of their mission to empower customers to own and protect their data on any SaaS platform, they plan to launch OwnBackup Recover for ServiceNow in the coming months.

 

About OwnBackup

OwnBackup is a leading SaaS data protection platform for some of the largest SaaS ecosystems in the world, including Salesforce, Microsoft Dynamics 365, and ServiceNow. Through capabilities like data security, backup and recovery, archiving, and sandbox seeding, OwnBackup empowers thousands of organizations worldwide to manage and protect the mission-critical data that drives their business.

 

Co-founded by seasoned data recovery, data protection, and information security experts, OwnBackup is a trusted independent software vendor (ISV) partner on the Salesforce AppExchange and Microsoft Marketplace. Headquartered in Englewood Cliffs, New Jersey, with research and development (R&D), support, and other functions in Israel, EMEA and APAC, OwnBackup is the partner of choice for some of the world’s largest users of SaaS applications.

Contacts

Media:

Colin Snell

press@ownbackup.com

Categories
Business Culture

Marotta Controls named a New Jersey Top Workplace for 2022

Aerospace and Defense Supplier Recognized for Inclusive and Innovative Company Culture

 

MONTVILLE, N.J. — (BUSINESS WIRE) — #additivemanufacturing—Marotta Controls, a rapidly growing aerospace and defense supplier, today announced that it has been named one of New Jersey’s top workplaces. Hosted by NJ Advance Media (NJ.com) in partnership with Energage, the statewide recognition program is based solely on employee survey responses and serves as a candid tool to assess corporate culture as well as the internal leadership impact and opportunity. Marotta Controls was one of 22 Aerospace and Defense companies evaluated nationwide, and ultimately ranked high in the mid-sized New Jersey companies category based on employee responses to the survey’s Culture Driver statements.


Marotta Controls’ performance-driven leadership strategy strives to instill a culture across all business units where new ideas and innovative concepts can be explored. Embracing that level of inspired creativity in a collaborative environment and focusing on employee engagement is largely what has influenced the company’s organic growth since it was founded in 1943.

 

“We deeply value our employee relationships, viewing them as long-term commitments not transactional engagements,” said Patrick Marotta, President and CEO, Marotta Controls. “We have an incredible staff with vision and passion for both engineering and business. Their contributions and support have enabled the company to achieve significant successes throughout our 79-year company history.”

 

This is Marotta Controls’ first year participating. At the time of the survey, the company’s employee base included approximately 450 individuals. Eighty-four percent responded, far exceeding the national participation average of 42 percent for all companies and 66 percent for Aerospace and Defense companies.

 

Notably, the respondents recognized the company as excelling in several crucial areas that shape company culture. Some of these areas include:

  • The company operating by strong values
  • Management caring about employees’ concerns
  • Employees feeling appreciated and that they are part of something meaningful
  • Individual learning, growth, and inclusion
  • Encouragement of new ideas and perspectives

 

“To be ranked by our team members as highly as we were demonstrates a mutual respect that we are truly honored to have earned. We take assessments like these very seriously and work to incorporate related feedback in meaningful ways. We’re proud to see that effort reflected in this year’s results,” added Patrick.

 

The complete list and ranking of New Jersey’s Top Workplaces will be formerly released later this quarter.

 

Methodology

Managed by the independent firm Energage, the NJ.com program is free and open to any organization with 50 or more employees. Staff members of nominated companies complete a questionnaire that addresses employee-centric issues from benefits and expectations to career opportunity and management support. Energage then uses its patented analytic tools and expertise gained from more than 16 years of culture research across 70,000 organizations to assess and report on the data.

 

About Marotta Controls

Founded in 1943, Marotta Controls is a fully-integrated solutions provider which designs, develops, qualifies and manufactures innovative systems and sub-systems for the aerospace and defense sectors. Our portfolio includes pressure, power, motion, fluid, and electronic controls for tactical systems, shipboard and sub-sea applications, satellites, launch vehicles, and aircraft systems. With over 200 patents, Marotta Controls continues to build on its legacy as a highly respected, family-owned small business based in the state of New Jersey. Twitter: @marottacontrols LinkedIn: Marotta Controls, Inc.

Contacts

Heather Ailara

211 Communications

+1.973.567.6040

heather@211comms.com

Katee Glass

Marotta Controls, Inc.

kglass@marotta.com

Categories
Business International & World

MetLife Investment Management Europe receives license from Central Bank of Ireland to manage and market investment strategies across European Economic Area

WHIPPANY, N.J. — (BUSINESS WIRE) — MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced that MetLife Investment Management Europe Limited (“MIM Europe”) has been authorized by the Central Bank of Ireland (“CBI”) to manage and market AIFs and UCITS, two vehicles through which European investors can best access MIM’s investment capabilities. Additionally, the license allows MIM Europe to offer and manage MIM’s full range of investment strategies across the European Economic Area (“EEA”).

Headquartered in Dublin, Ireland, MIM Europe will serve as the hub for MIM’s business in the EEA. Today, MIM has a significant presence in Europe across a range of client segments and countries. The authorization will enable broader access to the EEA market.

 

“This affirms our commitment to expand our offerings in Europe and will allow us to take an increasingly local approach to serving the market,” said Matthew Mosca, global head of the Institutional Client Group at MIM. “We have already seen demonstrated demand for our core investment products in Europe, and the CBI license will allow MIM to further leverage both our U.S. and Europe-based product and management capabilities in ways directly suited to European institutional investors.”

 

“The authorization of MIM Europe is a clear demonstration of the central role we expect Europe to continue to play in MIM’s international expansion, and of our desire to deliver our full breadth of investment capability to European investors,” said Nigel Murdoch, managing director and head of EMEA for MIM’s Institutional Client Group. “We look forward to collaborating with investors across Europe on the delivery of strong, long-term, sustainable investment returns.”

 

About MetLife Investment Management

MetLife Investment Management, the institutional asset management business of MetLife, Inc. (NYSE: MET), is a global public fixed income, private capital and real estate investment manager providing tailored investment solutions to institutional investors worldwide. MetLife Investment Management provides public and private pension plans, insurance companies, endowments, funds and other institutional clients with a range of bespoke investment and financing solutions that seek to meet a range of long-term investment objectives and risk-adjusted returns over time. MetLife Investment Management has over 150 years of investment experience and, as of December 31, 2021, had $669.0 billion in total assets under management.1

 

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com.

 

Endnotes

1 Total AUM is comprised of all MetLife general account and separate account assets and unaffiliated/third party assets, at estimated fair value, managed by MIM.

Contacts

For Media:
Dave Franecki

+1-973-264-7465

dave.franecki@metlife.com

Doug Allen, DLPR

+1 646 722-6530

Doug@dlpr.com

Categories
Business Local News

Asana BioSciences announces dosing of first patient in Phase 1 trial of ASN004, a novel 5T4-antibody-drug-conjugate

LAWRENCEVILLE, N.J. — (BUSINESS WIRE) — Asana BioSciences, LLC, a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in a Phase 1 trial for ASN004, an antibody drug conjugate (ADC) targeting the 5T4 oncofetal antigen (trophoblast glycoprotein), that is expressed in a wide range of malignant tumors but shows very limited expression in normal tissues. Higher 5T4 expression is associated with worse clinical outcome in non-small cell lung, head and neck, gastric, pancreatic, colorectal, and ovarian cancers.

ASN004 incorporates a novel single-chain Fv-Fc antibody linked to a clinically validated Auristatin F hydroxypropylamide cytotoxic payload, and drug to antibody ratio (DAR) of approximately 10-12. In preclinical cancer models, a single dose of ASN004 achieved complete and durable tumor regression leading to tumor-free survivors.

 

“5T4 is an ideal antigen target for payload delivery to tumor with high internalization rate dynamics combined with the high DAR and represents a clear opportunity for precision guided therapy as needed” said Dr. Anthony Tolcher, Director of Clinical Research, Next Oncology, San Antonio, Texas and the Principal Investigator of the Phase 1, multicenter, dose-finding study, designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of ASN004, in patients with advanced solid tumors in the US (NCT04410224).

 

“We are delighted to initiate the clinical development of ASN004. The broad tumor expression profile of 5T4 qualifies it as a promising target for cancer therapies, with potential to be the best-in-class ADC,” said Sandeep Gupta, PhD, Founder, President and Chief Executive Officer at Asana BioSciences. “ASN004 is the 6th novel program that Asana has successfully brought into the clinic, affirming our mission to provide new and better treatment options to patients,” added Dr. Gupta.

 

About Asana BioSciences, LLC

Asana BioSciences is a clinical stage biopharmaceutical company based in Lawrenceville, NJ. Asana is focused on discovery and development of novel targeted investigational medicines in immunology/inflammation and oncology.

 

Gusacitinib (ASN002) is an oral potent inhibitor of the Janus Kinase (JAK) family (JAK1, JAK2, JAK3 and TYK2) and Spleen Tyrosine Kinase (SYK). This potential best-in-class JAK/SYK inhibitor has been studied in ~350 patients with moderate-to-severe atopic dermatitis (NCT03531957) and chronic hand eczema (NCT03728504) and has demonstrated efficacy and good safety/tolerability.

 

ASN003 is a potent and highly selective inhibitor of B-RAF and PI3 Kinases. It has been evaluated in a Phase 1 trial in metastatic melanoma, colorectal and advanced non-small cell lung cancer, and other advanced solid tumors patients harboring BRAFV600 and PI3K pathway mutations (NCT02961283).

 

ASN008 is a novel, topical Na+-channel blocker with high functional selectivity for itch and pain sensing neurons without affecting motor neurons. In a Phase 1b study in atopic dermatitis patients, topical application of ASN008 showed rapid onset of pruritus relief (NCT03798561). ASN008 also has potential for the treatment of pain, urologic and other chronic conditions.

 

ASN009 is a selective antagonist of the purinergic P2X3 ion channel that is activated by extracellular ATP and involved in various pain, urological and respiratory disease conditions. ASN009 shows robust efficacy in a preclinical model of cough and is currently in preclinical development.

 

www.asanabiosciences.com

Contacts

Shashank Mahashabde

Asana BioSciences

997 Lenox Drive, Suite 220

Princeton Pike Corporate Center

Lawrenceville, NJ 08648

Ph: 609-557-1119

Shashank.Mahashabde@asanabio.com

Categories
Business Science

Marotta Controls’ oxygen-compatible solenoid valves deliver versatility while minimizing part numbers

Manifold-Mounted and Inline Direct Acting Valves Offer a Qualified, Cross-Application Solution to the Commercial Space Market

 

MONTVILLE, N.J. — (BUSINESS WIRE) — #additivemanufacturing–Today, Marotta Controls, a rapidly growing aerospace and defense supplier with a 65-year-plus heritage in spaceflight, announced that its latest direct acting solenoid valve is qualified for use in high pressure oxygen systems. Notably, the valve is also suitable for launch vehicle inert gas systems given its high flow capacity, smaller size, rapid response time, and overall cost-effectiveness. The manifold-mounted PLV405 can be configured with two or three ports and is proven to be reusable with a tested high lifecycle count.


Offering the same performance advantages, Marotta Controls also produces an inline model – the MV405. This valve is also available in 2-way or 3-way port configurations.

 

The PLV405 valves offer notable improvements over similar incumbent options, to include nearly double the flow capacity in a 7% lighter package with a 33% faster response time. They are constructed with alloys produced to the ATSM A36 standard.

 

“We understand the complexity of building and qualifying space vehicles. And we understand the importance of simplifying that process any way possible to speed manufacturing without compromising quality,” said Brian Ippolitto, Director, Aerospace Systems Engineering, Marotta Controls. “We view ourselves as more than just suppliers. We operate as true partners who aim to alleviate or at least minimize challenges wherever possible across the whole development cycle. Today, that intention manifests as producing a single, high performing valve with immense versatility.”

 

The 3-way valve is also available in a modified version that supports only Nitrogen, Helium and Air (no Oxygen).

 

The devices are qualified to the Air Force Space Command’s (AFSC) SMC-S-016 standard and are put through Marotta’s advanced cleaning and testing processes used for all space-bound hardware.

 

For more information, visit marotta.com.

 

About Marotta Controls

Founded in 1943, Marotta Controls is a fully-integrated solutions provider which designs, develops, qualifies and manufactures innovative systems and sub-systems for the aerospace and defense sectors. Our portfolio includes pressure, power, motion, fluid, and electronic controls for tactical systems, shipboard and sub-sea applications, satellites, launch vehicles, and aircraft systems. With over 200 patents, Marotta Controls continues to build on its legacy as a highly respected, family-owned small business based in the state of New Jersey. Twitter: @marottacontrols LinkedIn: Marotta Controls, Inc.

Contacts

Heather Ailara

211 Communications

+1.973.567.6040

heather@211comms.com

Katee Glass

Marotta Controls, Inc.

kglass@marotta.com

Categories
Business Science

Melinta Therapeutics acquires U.S. rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics

MORRISTOWN, N.J. — (BUSINESS WIRE) — Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today that it has acquired the U.S. rights to TOPROL-XL® (metoprolol succinate) and its Authorized Generic (AG) through an agreement between Melinta and New American Therapeutics Inc.

 

TOPROL-XL®, approved by the FDA in 1992, is a cardioselective beta-blocker indicated for the treatment of hypertension, alone or in combination with other antihypertensives; the long-term treatment of angina pectoris; and the treatment of stable, symptomatic (NYHA class II or III) heart failure of specific origins.

 

Said Christine Ann Miller, President and Chief Executive Officer, Melinta Therapeutics, “This acquisition immediately expands and diversifies our existing portfolio and serves as fuel for accelerating our long-term growth strategy and enhancing our profitability. We will continue to aggressively pursue portfolio expansion that aligns with our mission of providing innovative therapies for acute and life-threatening illnesses.”

 

“We are extremely proud of our work to provide access to this lifesaving medication,” said Michael Anderson, CEO, New American Therapeutics. “Melinta shares this same commitment to patient access. And they demonstrate that commitment through an impressive supply chain and distribution network that ensures this medication will continue to be available for those patients who need it.”

 

Melinta has begun the integration process to bring TOPROL-XL® into the company’s existing production, distribution and commercialization structure to ensure this important medication will continue to be made available without interruption.

 

Terms of the transaction were not disclosed.

 

About Melinta Therapeutics

Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses. Our portfolio currently includes five commercial-stage antibiotics: BAXDELA® (delafloxacin), KIMYRSA™ (oritavancin), MINOCIN® (minocycline) for Injection, ORBACTIV® (oritavancin), and VABOMERE® (meropenem and vaborbactam) and a commercial-stage cardiovascular product: TOPROL-XL® (metoprolol succinate). With an unsurpassed commitment to providers and the patients they serve, we work to ensure that all people who need our therapies can receive them. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Visit www.melinta.com for more information.

 

TOPROL-XL® is a registered trademark of AstraZeneca Pharmaceuticals LP and is used with permission.

 

About TOPROL-XL® (metoprolol succinate)

TOPROL-XL® is a beta-adrenergic blocker indicated for the treatment of:

  • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions
  • Angina Pectoris
  • Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure

 

IMPORTANT SAFETY INFORMATION

Contraindications

  • Known hypersensitivity to product components.
  • Severe bradycardia: Greater than first degree heart block, or sick sinus syndrome without a pacemaker.
  • Cardiogenic shock or decompensated heart failure.

 

Warnings and Precautions

  • Abrupt cessation may exacerbate angina pectoris or myocardial ischemia. Reduce dosage gradually over a period of 1 to 2 weeks and monitor the patient. Warn patients not to discontinue without their physician’s advice.
  • Heart Failure: Worsening cardiac failure may occur during up-titration.
  • Bronchospastic Disease: Avoid beta blockers.
  • Bradycardia, including sinus pause, heart block, and cardiac arrest have occurred with the use of TOPROL-XL. Patients with first-degree atrioventricular block, sinus node dysfunction, conduction disorders (including Wolff- Parkinson-White) or on concomitant drugs that cause bradycardia (digitalis glycosides, clonidine, and diltiazem and verapamil) may be at increased risk. Monitor heart rate.
  • Pheochromocytoma: Initiate therapy with an alpha blocker.
  • Major Surgery: Avoid initiation of high-dose extended-release metoprolol in patients undergoing noncardiac surgery. Do not routinely withdraw chronic beta blocker therapy prior to surgery.
  • Diabetes and Hypoglycemia: May mask tachycardia occurring with hypoglycemia.
  • Thyrotoxicosis: Abrupt withdrawal in patients with thyrotoxicosis might precipitate a thyroid storm.
  • Peripheral Vascular Disease: Can precipitate or aggravate symptoms of arterial insufficiency.
  • Patients may be unresponsive to the usual doses of epinephrine used to treat an allergic reaction.

 

Adverse Reactions

Most common adverse reactions: tiredness, dizziness, depression, shortness of breath, bradycardia, hypotension, diarrhea, pruritus, rash.

Contacts

Susan Blum

Chief Financial Officer

Melinta Therapeutics, LLC

908-617-1300

info@melinta.com

Categories
Business Lifestyle

AM Best Webinar: ‘Six critical ways to transform insurance to a lifetime partner’

OLDWICK, N.J. — (BUSINESS WIRE) — #insurance—AM Best will host a complimentary webinar entitled “Six Critical Ways to Transform Insurance Business to a Lifetime Partner,” sponsored by Zelros, on April 26, 2022, at 1 p.m. EDT. Customer churn and lost loyalty is costing insurers over $470 billion globally, much of it due to poor consumer experience. Join a panel of technology and insurance experts to share practices and concrete takeaways on how data analytics and AI are leveraged to digitally transform the business of insurance with a more-humanized experience, while proactively assessing risks, preventing loss and protecting people’s lives and assets.

Register now: https://www.ambest.com/webinars/zelros/index.html

Panelists include:

  • Linh Ho, CMO, Zelros
  • Niels Keuker, CEO, iptiQ Sales Solutions at iptiQ by Swiss Re
  • Seth Rachlin, EVP, global insurance leader, Capgemini
  • Deb Zawisza, senior principal, Aite-Novarica

 

Attendees can submit questions during registration or by emailing webinars@ambest.com. The event will be streamed in video and audio formats, and playback will be available to registered viewers shortly after the event.

 

Zelros is a pioneer in insurtech, transforming insurance distribution with its award-winning AI solution, enabling a unique customer and agent experience through hyper-personalized insurance recommendations across channels. The world’s largest insurance companies, such as BPCE Group, Crédit Agricole, Groupama, MAIF, Matmut, Baloise Group, AssurOne and Simpego, trust Zelros to help them stay competitive, boost client acquisition and cross-sell revenue, and adhere to Responsible AI governance. Zelros is headquartered in Paris with offices in Canada, Germany and Italy.

 

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

 

Copyright © 2022 by A.M. Best Company, Inc. and/or its affiliates.

ALL RIGHTS RESERVED.

Contacts

Lee McDonald
Group Vice President, Publication & News Services
+1 908 439 2200, ext. 5561
lee.mcdonald@ambest.com

Categories
Business Local News

Church & Dwight to report first quarter 2022 results

EWING, N.J. — (BUSINESS WIRE) — Church & Dwight Co., Inc. (NYSE:CHD) will host a conference call to discuss first quarter 2022 earnings results on April 28, 2022 at 10:00 a.m. Eastern time.

To participate, dial 877-322-9846 within the U.S. and Canada, or 631-291-4539 internationally, using access code 7619748. A replay will be available two hours after the call at 855-859-2056 using the same access code. You can also participate by visiting the Investor Relations section of the Company’s website at www.churchdwight.com.

 

Church & Dwight Co., Inc. (NYSE: CHD) founded in 1846, is the leading U.S. producer of sodium bicarbonate, popularly known as baking soda. The Company manufactures and markets a wide range of personal care, household, and specialty products under recognized brand names such as ARM & HAMMER®, TROJAN®, OXICLEAN®, SPINBRUSH®, FIRST RESPONSE®, NAIR®, ORAJEL®, XTRA®, L’IL CRITTERS® and VITAFUSION®, BATISTE®, WATERPIK®, FLAWLESS®, ZICAM® and THERABREATH®. These fourteen key brands represent approximately 80% of the Company’s products sales. For more information, visit the Company’s website.

Contacts

Rick Dierker

609-806-1900